Arthritis during interferon beta-1b treatment in multiple sclerosis.
Interferon beta (IFN-beta) is the most widely prescribed disease-modifying drug for multiple sclerosis (MS). Therapy with IFN-beta may be associated with a number of adverse reactions The development or exacerbation of other autoimmune diseases is a rare but reported side effect of IFN-beta therapy. In this case report, we present clinical and laboratory findings of two MS patients who developed arthritis during IFN-beta1b treatment, probably of autoimmune origin.
Altintas
A
A
Department of Neurology, Cerrahpasa School of Medicine, 34300 Istanbul, Turkey. aaltintas.md@superonline.com
Alici
Y
Y
Melikoğlu
M
M
Siva
A
A
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000328:Adult; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001168:Arthritis / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000009:adverse effects*; D008727:Methotrexate / Q000008:administration & dosage; D009103:Multiple Sclerosis / Q000188:drug therapy*; D013256:Steroids / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D018501:Antirheumatic Agents; D013256:Steroids; D000068576:Interferon beta-1b; D016899:Interferon-beta; D008727:Methotrexate